Comparative Pharmacology
Head-to-head clinical analysis: LUPRON versus SUPPRELIN LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUPRON versus SUPPRELIN LA.
LUPRON vs SUPPRELIN LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) agonist. Chronic administration suppresses pituitary gonadotropin secretion, leading to decreased testosterone and estradiol levels.
SUPPRELIN LA is a sterile, biodegradable, subcutaneous implant containing histrelin acetate, a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). After an initial transient increase, continuous administration results in downregulation of pituitary GnRH receptors, leading to suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing gonadal sex steroid production (testosterone in males, estradiol in females) to castrate levels.
3.75 mg intramuscularly once monthly or 11.25 mg intramuscularly once every 3 months. For endometriosis, 3.75 mg intramuscularly monthly for up to 6 months. For central precocious puberty, 0.3 mg/kg intramuscularly every 28 days.
50 mg subcutaneously once every 12 months (implant placed in inner upper arm).
None Documented
None Documented
Terminal half-life approximately 3 hours after subcutaneous administration; in patients with renal impairment, half-life may be prolonged
Terminal half-life approximately 3-4 hours; clinical suppression of luteinizing hormone and testosterone sustained for 4 weeks due to depot formulation.
Renal (primarily as metabolites), <5% unchanged; fecal ~5%
Renal: <5% unchanged; hepatic metabolism; fecal elimination of metabolites.
Category C
Category C
GnRH Agonist
GnRH Agonist